Technology
Health
Biotechnology

Idera Pharmaceuticals

$2.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.15%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IDRA and other stocks, options, ETFs, and crypto commission-free!

About

Idera Pharmaceuticals, Inc. Common Stock, also called Idera Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. Read More The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.

Employees
36
Headquarters
Exton, Pennsylvania
Founded
1989
Market Cap
71.98M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
369.86K
High Today
$2.67
Low Today
$2.49
Open Price
$2.62
Volume
213.60K
52 Week High
$17.12
52 Week Low
$2.25

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America

News

Yahoo FinanceMay 10

Idera Pharmaceuticals, Inc. Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA). As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. IDRA. The stock has moved higher by 25% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider IDRA...

138
Yahoo FinanceMay 2

Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates

Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

182
Yahoo FinanceMay 1

Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know

Wall Street expects a year-over-year increase in earnings on lower revenues when Idera Pharmaceuticals (IDRA) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

39

Earnings

-$0.59
-$0.42
-$0.25
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.